Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EXACT Therapeutics AS ( (DE:56F) ) just unveiled an update.
EXACT Therapeutics AS announced that during their upcoming Annual General Meeting, separate votes will be conducted for each board of directors candidate. This decision allows shareholders to submit proxies or advance votes through the VPS or specified forms, ensuring a more tailored voting process. This move could potentially impact the company’s governance and strategic direction by allowing more precise shareholder input.
More about EXACT Therapeutics AS
EXACT Therapeutics is a clinical-stage precision medicine company that focuses on utilizing ultrasound and microbubbles for targeted drug delivery in oncology. Their proprietary Acoustic Cluster Therapy (ACT®) is designed to enhance the delivery of therapeutic agents across various medical conditions, including cancer and brain diseases. The company is publicly traded on Euronext Growth Oslo under the ticker EXTX.
Average Trading Volume: 17,239
Current Market Cap: NOK182.2M
See more insights into 56F stock on TipRanks’ Stock Analysis page.